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Background: Given the current lack of disease-modifying therapies, it is important to explore new models of
longitudinal care for older adults with dementia that focus on improving quality of life and delaying functional
decline. In a previous clinical trial, we demonstrated that collaborative care for Alzheimer’s disease reduces patients’
neuropsychiatric symptoms as well as caregiver stress. However, these improvements in quality of life were not
associated with delays in subjects’ functional decline.
Trial design: Parallel randomized controlled clinical trial with 1:1 allocation.
Participants: A total of 180 community-dwelling patients aged ≥45 years who are diagnosed with possible or
probable Alzheimer’s disease; subjects must also have a caregiver willing to participate in the study and be willing
to accept home visits. Subjects and their caregivers are enrolled from the primary care and geriatric medicine
practices of an urban public health system serving Indianapolis, Indiana, USA.
Interventions: All patients receive best practices primary care including collaborative care by a dementia care
manager over two years; this best practices primary care program represents the local adaptation and implementation
of our prior collaborative care intervention in the urban public health system. Intervention patients also receive in-
home occupational therapy delivered in twenty-four sessions over two years in addition to best practices primary care.
The focus of the occupational therapy intervention is delaying functional decline and helping both subjects and
caregivers adapt to functional impairments. The in-home sessions are tailored to the specific needs and goals of each
patient-caregiver dyad; these needs are expected to change over the course of the study.
Objective: To determine whether best practices primary care plus home-based occupational therapy delays functional
decline among patients with Alzheimer’s disease compared to subjects treated in the control group.
Outcomes: The primary outcome is the Alzheimer’s Disease Cooperative Studies Group Activities of Daily Living Scale;
secondary outcome measures are two performance-based measures including the Short Physical Performance Battery
and Short Portable Sarcopenia Measure. Outcome assessments for both the caregiver-reported scale and subjects’
physical performance scales are completed in the subject’s home.
Randomization: Eligible patient-care giver dyads will be stratified by clinic type and block randomized with a
computer developed randomization scheme using a 1:1 allocation ratio.
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Blinding: Single blinded. Research assistants completing the outcome assessments were blinded to the subjects’
treatment group.
Trial status: Ongoing
ClinicalTrial.Gov identifier: NCT01314950; date of completed registration 10 March 2011; date first patient
randomized 9 March 2011
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Dementia is a growing public health problem with the
prevalence varying from 3 to 11% among people aged
65 years and over [1]. Dementia leads to a high burden
of suffering for patients, families, and society with an an-
nual estimated cost of $100 billion in the US [2,3]. There
were an estimated 7 million cases of dementia in the US
in 2000 and this number may grow to 18.5 million by
the year 2050 [4]. Sloane and colleagues estimated that
the number of Alzheimer’s disease (AD) cases in the US
would rise from 2.7 million in 2005 to 10 million in
2050 if there are no important advances in current treat-
ment strategies [5]. If treatments were discovered that
both delayed disease onset and slowed disease progres-
sion, the number of cases would still rise to more than 6
million [5]. Even under optimistic scenarios of improved
treatment, we must prepare to care for a growing popu-
lation of older adults with AD. Thus, research efforts
must focus on care in addition to cure.
Most older adults with AD receive their medical care
in primary care settings yet most primary care physicians
care for fewer than two dozen older adults with AD
[6,7]. Researchers and policy makers consistently docu-
ment suboptimal quality and poor outcomes among
older adults receiving the usual care of generalist physi-
cians [8-11]. There have been three general responses to
this persistent quality problem in primary care [12,13].
The first has been to improve the knowledge, skills, atti-
tudes, and behavior of primary care physicians. The sec-
ond approach has been to add resources into the
primary care setting. The third approach has been to vir-
tually expand primary care through information technol-
ogy, facilitated access to care managers or specialists,
and improved coordination of care such as patient-
centered medical home approaches [14]. A non-primary
care approach has been to simply move high-need
patients to another setting such as a specialty dementia
clinic. These interventions are not mutually exclusive
and each provides certain benefits.
In 2006, we reported the results of a randomized con-
trolled clinical trial testing the effectiveness of collabora-
tive care compared with augmented usual care among
primary care patients with AD [15]. The primary care-based collaborative care intervention resulted in statisti-
cally significant improvement in the quality of care and
in behavioral and psychological symptoms for patients
and their caregivers. The improvements we reported in
this trial on the intervention subjects’ neuropsychiatric
inventory scores were among the highest reported in the
literature at that time [15]. However, guideline-level care
did not slow the rate of patients’ functional decline com-
pared with augmented usual care. Notably, functional
decline among older adults with AD is often due to
comorbid conditions in addition to the AD [16]. Also,
functional decline, as compared with behavioral symp-
toms, may be a stronger predictor of subsequent
institutionalization among older adults with AD [17].
Several short-term studies focusing specifically on func-
tional decline among patients with AD and related
dementias have shown the potential to slow functional
decline through home-based interventions [18-20]. The
current study builds on our past work and those of
others by integrating home-based occupational therapy
interventions with our primary care-based collaborative
care intervention to delay functional decline.
The specific aim of this study is to conduct a two-year
randomized, controlled clinical trial to delay functional
decline among older adults with AD by comparing a
control group receiving best practice primary care with
an intervention group receiving best practice primary
care plus a home-based occupational therapy interven-
tion. We will test the primary hypothesis that subjects
with AD in the intervention group will have better func-
tion at two years compared with the best practice pri-
mary care control group, as measured by the
Alzheimer’s Disease Cooperative Studies (ADCS) Group
Activities of Daily Living (ADL) Inventory. Because this
inventory is self-reported by the caregiver, we will also
assess patient function using two physical performance
tests. ‘Best practice primary care’ is not equivalent to the
usual care of most primary care practices. In prior work
in primary care settings, we have demonstrated the lim-
itations of usual care for patients with dementia [7,9].
Thus, we are seeking to determine if our combined
intervention can slow the rate of functional decline
when compared with best practice based on our prior
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tional therapy will bring incremental benefits in behav-




The overall study design is shown in Figure 1. This is a
randomized single blind controlled clinical trial with a
parallel design and a 1:1 allocation ratio. We will enroll a
total of 180 care-recipient and caregiver dyads with all
care-recipients meeting diagnostic criteria for possible or
probable AD. The study was approved by the Indiana Uni-
versity - Purdue University Indianapolis Institutional Re-
view Board (IRB number 0907–82). Study safety is also•AD-dementia
•Age ≥ 45 years
Community-dwel








Outcomes assessed at 6
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Stratification
Figure 1 Study design.monitored by an Independent Data Safety Monitor who is
a single individual approved by the funding agency and
selected from an external institution. The role of the Inde-
pendent Data Safety Monitor is to review study progress,
data quality, and unanticipated adverse events.
Setting
The study site is Wishard Health Services, an urban public
health system serving medically indigent patients in In-
dianapolis. Wishard Health Services includes a 350-bed
hospital and a network of eight primary care centers in In-
dianapolis. It also includes a Senior Care program staffed
by faculty in an academic geriatric medicine program that
includes services such as an Acute Care for Elders Unit, a
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Health [21]. Geriatric ambulatory care services include the
Healthy Aging Brain Center (HABC) [22] and the Aging
Brain Care-Medical Home (ABC-MedHome) [23]. Both of
the aging brain clinic sites are local adaptations and imple-
mentation of the collaborative care program tested in a
prior clinical trial [15]. Both the HABC and the ABC-
MedHome support primary care providers through col-
laborative care, however, HABC provides this care in a de-
mentia care clinic while the ABC-MedHome provides this
care in the home setting. Some patients may be seen in
both programs.
Type of participants
Patients are recruited from the HABC, the Center for
Senior Health, and the primary care practices affiliated
with Wishard Health Services that are served by the
ABC-MedHome. The older adult population cared for at
Wishard included approximately 7,500 adults aged
65 years and older in 2009. Nearly all of these patients
have at least one visit to their primary care physician
every two years. Based on our prior studies, we have a
wealth of data on this population. Briefly, approximately
68% are women, approximately 64% are African-
American, approximately 40% had ≤8 years of education,
and approximately 50% are dually eligible for both Medi-
care and Medicaid. The prevalence of dementia is 6%
based on prior formal screening programs in these pri-
mary care clinics [7]. Chronic medical illnesses are com-
mon including hypertension (63%), arthritis (30%),
diabetes mellitus (25%), chronic obstructive lung disease
(18%), coronary artery disease (15%), severe obesity
(14%), cancer (10%), and congestive heart failure (8%),
among others [7,9,16,24,25].
Patients are eligible if they are aged 45 years and older
and have a diagnosis of possible or probable AD, includ-
ing those patients who may have a mixed dementia. Ori-
ginal eligibility criteria included age 65 years and older,
but this age limit was reduced based on interest in the
study by younger potential subjects at the outset of the
trial. Eligibility criteria also include: receiving primary
care at Wishard Health Services, community-dwelling,
English-speaking, a caregiver willing to participate in the
study, and willing to receive home visits. Caregiver eligi-
bility criteria includes age 18 years or older, English-
speaking, and regular access to a telephone. For patients
meeting eligibility criteria, research personnel assigned
to each clinical site obtain informed consent from the
patient and the family caregiver. For patients unable to
provide informed consent due to their level of cognitive
impairment, we seek to obtain assent from the patient as
well as informed consent from their legally authorized
representative. Prior to randomization and within two
weeks of enrollment, patients and their caregiverscomplete an in-home baseline assessment by a profes-
sional research assistant. This research assistant is
blinded to the subjects’ ultimate randomization status
and is not involved in delivering the intervention. Enroll-
ment will take place over 2.5 years (30 months) with an
enrollment target of 180 subjects and their caregivers.
Description of the control condition
All enrolled patients and their caregivers (both best
practice primary care and intervention patients and re-
gardless of their enrollment site) will receive collabora-
tive care for dementia through the ABC-MedHome with
or without HABC. All subjects will be provided each of
the components of best practice primary care as listed in
the overview below:
 written materials and face-to-face counseling about
their diagnosis
 written materials describing local community
resources, including access to the local chapter of
the Alzheimer’s Association
 written consultation note to the patient’s primary
care physicians communicating the results of the
diagnostic assessment and the patient’s participation
in the study
 collaborative care management including:– medical co-management within the ABC-
MedHome in collaboration with the patient’s
primary care physician and the geriatrician,
dementia-care advanced practice nurse and social
worker affiliated with the ABC-MedHome,
including:
– treatment with cholinesterase inhibitors (or
memantine) unless contraindicated;
– education on communication skills; caregiver
coping skills; and legal or financial advice;
– a caregiver guide provided by the Alzheimer's
Association;
– enrollment in the local Alzheimer’s Associations
safe return program;
– treatment of behavioral disturbances based on
established protocols that first emphasize non-
pharmacological approaches;
 longitudinal telephone-based support
 tracking of patient outcomes including
behavioral symptoms of dementia
 access to a monthly support group for
caregivers within the targeted primary care
clinics.We consider all of the above ‘best practice primary
care’ because they encompass the collaborative care
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cause these interventions are not typical of usual care,
we recognized that the true impact of the intervention
on behavioral outcomes may appear diminished in our
results. However, we are trying to determine if the
addition of home-based occupational therapy is able to
forestall functional decline that the prior intervention
did not achieve. Best practice primary care will be pro-
vided for both experimental groups for 24 months. This
care is led by the patient’s primary care physician and a
geriatric nurse practitioner who serves as the dementia
care manager. One care manager can provide collabora-
tive care to about 80 to 100 patients in steady state.
Caregivers and patients are seen by the dementia care
manager at home, in the primary care clinic, or in other
clinical sites, but home visits are the most common.
Early contacts are dominated by face-to-face meetings
and later contacts tend to be dominated by telephone
contacts, depending on the clinical course of the patient
and caregiver.Table 1 Overview of occupational therapy (OT) in-home inter
Time OT intervention with care-recipient
Week One Initial Evaluation, CAMP, FoF, Berg, FIM, MNA, and
Week Two Discuss care plan with patient and caregiver Set a
New Task: Identify meaningful activity
Week Four Review care plan with patient and caregiver
New Tasks: ADL training/Transfer training
Week Six New Tasks: Begin strength training and exercise
provide safety information
Focus on meaningful activity
Week Eight Review ADL and exercise training
Address cognitive training
Time for meaningful activity
New Task: Medication management
Week Ten Review ADL training and exercise programming
Address meaningful activity
New Task: IADL training
Week Twelve Review ADL training and exercise programming
Time for meaningful activity
Address cognitive training
New Task: Identify one way to increase social pa
Week Sixteen Review ADL training and exercise programming
Review IADL training
Review safety information
Time for meaningful activity
ADL, activities of daily living; ACLS, Allen’s Cognitive Level Screen; Berg, Berg Balanc
Functional Independence Measure; FoF, Fear of Falling; IADL, Instrumental ActivitiesAt each contact with the care manager, caregivers
complete the Health Aging Brain Care (HABC) Monitor.
The HABC Monitor includes 31 items covering the four
clinical relevant domains of dementia symptoms; cognition,
functional deficit, behavioral/psychological, and caregiver
burden. Each item has four categories of responses that use
the frequency of the target problem in the past two weeks
and has a similar anchor. Total scores on the HABC Moni-
tor vary from 0 to 124 with higher scores indicating greater
patient symptomatology and caregiver stress. The HABC
Monitor demonstrated good internal consistency (0.73 to
0.92); test-retest reliability; construct validity indicated by
correlations with the caregiver-reported Neuropsychiatric
Inventory (NPI) total score and NPI caregiver distress
score; responsiveness to three-month change compared
to NPI ‘reliable change’ groups; and known-groups validity
indicated by significant separation of Mini Mental
Status Examination (MMSE) severity groups and clinical
diagnostic groups. (Description and psychometric proper-
ties available at [http://www.indydiscoverynetwork.org//vention
OT intervention with caregiver
ACLS Identify goals with patient and caregiver Identify
patient and caregiver abilities Coordinate plans
with dementia care manager
ctivity goals Discuss care plan with patient and caregiver
CG Goal: Decrease risk of caregiver injury
New Task: Train caregiver to safely assist in
activities of daily living and transfer training
and New Tasks: Begin strength training and exercise
Issue safety information
Focus on meaningful activity
Review ADL training, cognitive training, and
exercise programming
New Task: Medication management
Review ADL training and exercise programming
New Task: Work with caregiver to identify IADL
needs
Review ADL training and exercise programming
rticipation
Review ADL training and exercise programming
Review IADL training
Review safety information
e Scale; CAMP, Caregiver Assessment of Management Problems; FIM,
of Daily Living; MNA, Mini Nutritional Assessment.
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giver's reports of the patient’s current symptoms, individua-
lized recommendations are made regarding how to manage
a patient's behavioral symptoms [26]. Items reported by the
caregiver dictate activation of specific behavioral interven-
tion protocols by the care manager. There are ten protocols
including personal care, repetitive behavior, mobility, sleep
disturbances, depression, agitation or aggression, delusions
or hallucinations, the caregiver's physical health, driving
safety, nutrition, and delirium. Each of these protocols fo-
cuses first on non-pharmacological interventions. If the
non-pharmacological approach does not help, the care
manager collaborates with the primary care physician to
consider the protocol-based drug therapy for those behav-
ioral problems that could be amenable to pharmacologic
intervention (for example, depression).
The primary care physician and the care manager have
access to support and expert back-up from providers in
the HABC. This support can occur either through tele-
phone consultation or face-to-face meetings with the care
manager. The care manager and primary care physician
can also utilize referral to specialty care. The care manager
is supported by a Web-based longitudinal tracking system
that manages the schedule for patient contacts, tracks the
patient's progress and current treatments, and provides a
mechanism for communicating the patient's and caregi-
ver's current clinical status to the entire care team.
Patients and their caregivers will also be offered access to
support groups affiliated with their clinic.
Description of the intervention condition
The intervention group receives all of the components of
best practice primary care described above. In addition,
this group receives a home-based intervention designed to
slow functional decline. The main framework of the inter-
vention is based on general occupational therapy princi-
ples and prior published research [18-20,27]. Our main
goal is to support and augment self-care functioning cap-
ability of the patient as identified by goals established in
negotiation with the patient and caregiver. Thus, the focus
is to lessen the impact of the dementing illness and at-
tendant comorbid conditions to minimize: (a) decline in
the patients’ functioning and physical performance abil-
ities; (b) caregivers’ stress, and (c) likelihood that theTable 2 Additional outcome data
Completed with care-recipient
Mini Mental State Examination (MMSE) [46]
Word List Learning Test [48]
Mini Nutritional Assessment (MNA) [32]
Blood pressure, height, and weight
body composition (by bioelectrical impedance analysis)patient will need formal services. The intervention takes
place in the patient’s home and is led by an occupational
therapist. The occupational therapist completes an initial
evaluation to develop a formal care plan that is tailored to
the needs of the individual patient-caregiver dyads. Spe-
cific therapeutic interventions will be tailored for each in-
dividual or caregiver dyad based on the standardized
evaluation and patient and caregiver goal identification.
Thus, we expect that each dyad’s specific constellations of
training and support will vary. The content of the occupa-
tional therapy initial assessment includes: Caregiver As-
sessment of Management Problems (CAMP) [28]; Fear of
Falling (FoF); Berg Balance Scale [29]; Functional Inde-
pendence Measure (FIM) [30]; Allen’s Cognitive Level
Screen (ACLS) [31]; and the Mini Nutritional Assessment
(MNA) [32].
An overview of the intervention is summarized in
Table 1. The five assessment tools described above are
completed at the beginning of each of the three home-
based cycles to tailor the home-based component for in-
dividual dyads at each cycle. The therapist may also re-
peat this assessment at any time that they adjudge a
major change in the patient’s clinical status. Thus, at
minimum, this evaluation is done at baseline, 16 weeks
from baseline, and 48 weeks from baseline (three times)
and at minimum, three care plans will be completed.
There will be three cycles of the home-based interven-
tion over two years. In the first cycle, there will be eight
90-minute sessions delivered approximately every other
week over 16 weeks with a telephone call in intervening
weeks. A new task is introduced with each visit based on
a mutually agreed upon care plan. Additional phone
contacts are allowed to assist with problem solving and
address interval problems. At the end of cycle one
(16 weeks), the occupational therapist will repeat the
standardized assessment, construct a newly tailored care
plan, and then complete another eight-session cycle, but
in the second cycle the eight home visits will be spaced
by four weeks and therefore take place over 32 weeks. In
the second year, (the third cycle of the home-based com-
ponent), the protocol will also begin with the same as-
sessment and a newly tailored protocol. In the third
cycle, the eight home visits will take place over one year.
Thus, each patient will receive up to twenty-four 90-Completed with caregiver
ADCS Resource Use Instrument [47]
Patient Health Questionnaire-9 (PHQ-9) [49]
Generalized Anxiety Disorder-7 (GAD-7) Scale [50]
Satisfaction with the care
Adverse Event Checklist
Table 3 Process of care data
Provider contacts
Dementia care specialists (APN, RN, or MSW)
Number of home visits, mean
Number of clinic visits, mean
Number of telephone contacts, mean
Occupational therapist
Number of home visits, mean
Number of clinic visits, mean
Number of telephone contacts, mean
Total contacts
Other rehabilitation therapist visits
Physicians
Number of primary care MD visits, mean
Number of specialty dementia MD visits, mean
Number of other specialty MD visits, mean
Dementia Care
Pharmacologic management
Number (%) receiving anti-dementia drug
Number (%) receiving antipsychotic drug
Number (%) receiving antidepressant
Number (%) receiving sedative-hypnotic
Anticholinergic burden
Percentage on definite anticholinergic medications
Percentage on cholinesterase inhibitor and anticholinergic medications
Percentage with anticholinergic medication discontinued
Non-pharmacologic management
Family conference to reveal diagnosis
Written educational materials
Contact information for Alzheimer’s Association
Number of behavioral protocols activated
Number receiving dietary supplement
APN, advanced practice nurse; MD, medical doctor or doctor of medicine or
physician; MSW, master of social work; RN, registered nurse.
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more closely clustered in the first year.
Outcome measures
Outcomes measures are completed in the home by a team
of two research assistants who are blinded to the dyad’s







0.23σ to 0.31σ 0.23σ (mean of 0.20σ and 0.26σfocuses on the interview of the caregiver and the second
research assistant focuses on the performance-based mea-
sures of the care-recipient. Outcome assessments are
completed at baseline six, twelve, eighteen, and twenty-
four months.
Primary outcome measure
The primary outcome measure is the ADCS Group
Activities of Daily Living Inventory. This is a 23-item in-
ventory developed by the ADCS Group that is adminis-
tered to the patient’s caregiver by a trained interviewer.
The caregiver is asked to focus on the patient’s perform-
ance over the past month. Notably, the caregiver reports
on what the patient actually did rather than an assess-
ment of what the patient might be able to do. Thus, the
Inventory focuses on observed actions. The items were
chosen from among 45 items rating activities of daily liv-
ing reported in the literature. The instrument assesses
the traditional basic activities of daily living as well as
variations on instrumental activities of daily living and a
number of more complex and explicit self-care tasks
[33]. Scores vary from 0 to 75 with higher scores indicat-
ing greater levels of function.
Secondary outcome measures
The Neuropsychiatric Inventory (NPI) has been adopted
by the ADCS Group to obtain information on the pres-
ence of psychopathology in behavioral areas including
delusions, apathy, hallucinations, disinhibition, agitation,
depression, aberrant motor behavior, anxiety, night-time
behavior, and euphoria. Scores vary from 0 to 144 with
higher scores representing worse symptoms. The Inven-
tory is interviewer administered to a caregiver. The NPI
can be used to assess changes in the patient’s behavior
over the past month or other specified time intervals. If
the caregiver reports the presence of psychopathology,
there are follow-up questions to assess frequency, sever-
ity, and the level of caregiver distress due to the behav-
ior. Thus, the instrument is specifically designed to also
measure caregiver distress (possible scores vary from 0
to 60). The administration time is about 20 minutes.
The test has excellent reliability and validity [34-36].
The Short Physical Performance Battery (SPPB) is a
standardized measure of lower extremity physical per-
formance that includes walking, balance, and power
tasks, and has been used in a broad range of epidemio-
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placement, hospital admission, and mortality [40-44].
The SPPB score is based on timed measures of standing
balance, walking speed, and repeated chair rises. Scores
vary from 0 to 12 with higher scores indicating better
function.
The Short Portable Sarcopenia Measure (SPSM) was
conceptualized as a measure of sarcopenia that com-
bines muscle quantity and function [45]. The SPSM can
be used to follow change in muscle status over time with
each person as his or her own control. The scale is based
on timed chair rises, lean mass, and grip strength
divided by height. Scores vary from 0 to 18 with higher
scores indicating better function.
Additional outcome and process of care data collected
for this study are listed in Tables 2 and 3. These data
are collected at baseline, and then at 6, 12, 18, and
24 months from the time of the baseline date.Sample size
The targeted sample size is 180 patients. The study is
designed to have at least 80% power for testing the fol-
lowing hypothesis based on two-tailed tests at 5% signifi-
cance level: subjects with AD in the intervention group
will have improved function at two years compared with
the best practice primary care control group. The pri-
mary outcome is the ADCS Group ADL Inventory mea-
sured at 24 months. The expected effect size for the
primary outcome of ADL Inventory in Table 4 is based
on clinically important differences that can be realistic-
ally expected from published studies [18,20,27]. Since
baseline values will always be included as covariates in
all between-group comparisons, the residual variance
used in power calculation is equal to the population
within-group variance multiplied by (1-correlation2),
with correlations estimated from our prior clinical trial
[15]. We estimated that we will have 82% power to de-
tect the between-group difference in ADL Inventory at
24 months. The software package nQuery was used to
conduct the sample size calculation [51].
Randomization
Randomization will be conducted at the patient level
stratified by clinic (Healthy Aging Brain Center or all
other ambulatory care clinics). The statistical software
SAS (SAS Institute Inc. 2008. SAS/STAT 9.2 User’s Guide.
SAS Institute Inc., Cary, NC, USA) was used to generate
the randomization scheme. Sequentially numbered sealed
envelopes containing the randomization assignment for
patient for each of the two clinic types were prepared by
the study statistician. Actual randomization results will be
compared to pre-planned randomization schedule to en-
sure randomization integrity.Data management
Outcome assessment and OT measures are entered into a
REDCap (Research Electronic Data Capture) database, an
electronic data capture tool hosted at Indiana University
Clinical Translational Science Institute [52]. REDCap is a
secure, Web-based application designed to support data
capture for research studies, providing validated data
entry, audit for tracking data manipulation and export
procedures, automated export procedures and procedures
for importing data from external sources.
Primary analysis
The efficacy of the clinical trial will be tested on the pri-
mary outcome of ADL Inventory measured at 24 months.
Analysis of covariance (ANCOVA) will be used for test-
ing the effect of the intervention while controlling for
the baseline ADL Inventory and randomization stratum.
We will perform an intention-to-treat analysis on all
patients who have the ADL Inventory measured at base-
line and at least one other value. Since only those sub-
jects who complete the 24-month assessment will have
the primary outcomes measured, multiple imputation
will be used in cases of missing data at 24 months.
Multivariate normal (MVN) models will be used as the
imputation models using patients’ characteristics, base-
line and post baseline outcome variables to impute miss-
ing ADL values, as previous research indicated the
MVN method performed well when compared to the
completed cases only analysis or the last observation
carried forward technique in simulation studies [53].
These imputed outcomes will then be used in the pri-
mary efficacy analyses according to established guide-
lines [54]. ANCOVA models will also be used to test the
secondary hypothesis that the combined intervention
will improve the subject’s performance on the two phys-
ical performance scales and both patients’ behavioral
symptoms and caregiver stress, both of which are cap-
tured by the NPI.
Discussion
The multifaceted intervention tested in this trial builds
upon past research in three ways. First, we are integrat-
ing a comprehensive set of biopsychosocial care manage-
ment recommendations for older adults with dementia
and their caregivers. These recommendations encompass
not only a complex set of medical management options,
but also a team-based approach that includes nursing,
social work, and rehabilitation sciences care strategies.
Second, the intervention is substantially longer than the
typical Alzheimer’s disease intervention reported in the
literature. Both control and intervention patients will re-
ceive care management over a two-year period. Third,
we have moved the bulk of this intervention, including
the medical management, into the patient’s home to
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care. One of the most important limitations in the pri-
mary care environment is space. The study is ongoing
and has now completed 12 months of enrollment with
75 patient-caregiver dyads enrolled as of February 2012.
There have been no serious adverse events to date and





ABC-MedHome: Aging Brain Care-Medical Home; ACLS: Allen’s Cognitive
Level Screen; ADL: Activities of Daily Living; AD: Alzheimer’s disease;
ADMIT: Alzheimer’s Disease Multiple Intervention Trial; ADCS: Alzheimer’s
Disease Cooperative Studies; ANCOVA: analysis of covariance; APN: advanced
practice nurse; Berg: Berg Balance Scale; CAMP: Caregiver Assessment of
Management Problems; FIM: Functional Independence Measure; FoF: Fear of
Falling; GAD: Generalized Anxiety Disorder; HABC: Healthy Aging Brain
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